(NASDAQ: AQST) Aquestive Therapeutics's forecast annual revenue growth rate of 38.3% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.41%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.61%.
Aquestive Therapeutics's revenue in 2025 is $43,397,000.On average, 12 Wall Street analysts forecast AQST's revenue for 2025 to be $5,583,472,466, with the lowest AQST revenue forecast at $5,130,474,908, and the highest AQST revenue forecast at $5,867,129,704. On average, 12 Wall Street analysts forecast AQST's revenue for 2026 to be $8,525,333,530, with the lowest AQST revenue forecast at $6,217,278,638, and the highest AQST revenue forecast at $10,713,337,359.
In 2027, AQST is forecast to generate $14,768,476,829 in revenue, with the lowest revenue forecast at $9,792,213,856 and the highest revenue forecast at $19,693,742,500.